☆Aisling Capital Management LP
Quality Q
0.895
AUM ($M)
472
Positions
14
Turnover
0.08
Top-10 wt
99%
Herfindahl
0.539
History (qtrs)
6
Excess Return
-37.1%
AI Eval Run AI Eval
Holdings · 14 positions · portfolio value $472M
| Ticker | Name | Activity | Security Type | Weight | Δ Weight | Value ($M) | Shares | Δ Shares | Qtrs Held | Excess Return |
|---|---|---|---|---|---|---|---|---|---|---|
| ☆BBIO funds › | BRIDGEBIO PHARMA INC | TRIM | — | 72.5% | -6.9% | 341.8 | 4,589,611 | -500,000 | 5 | — |
| ☆GLUE funds › | MONTE ROSA THERAPEUTICS INC | HOLD | — | 8.0% | +2.6% | 37.6 | 1,555,664 | +0 | 5 | — |
| ☆SNDX funds › | SYNDAX PHARMACEUTICALS INC | HOLD | — | 6.1% | -0.4% | 28.8 | 1,316,806 | +0 | 5 | — |
| ☆CMPS funds › | COMPASS PATHWAYS PLC | HOLD | — | 4.3% | +2.6% | 20.3 | 1,432,336 | +0 | 5 | — |
| ☆BCAX funds › | BICARA THERAPEUTICS INC | HOLD | Common Stock | 3.6% | +1.2% | 16.9 | 568,919 | +0 | 5 | — |
| ☆BBOT funds › | BRIDGEBIO ONCOLOGY THERAPEUT | HOLD | — | 1.6% | -0.3% | 7.8 | 1,018,018 | +0 | 4 | -37.1% |
| ☆SRRK funds › | SCHOLAR ROCK HLDG CORP | HOLD | — | 0.9% | +0.1% | 4.2 | 77,031 | +0 | 4 | +45.4% |
| ☆URGN funds › | UROGEN PHARMA LTD | HOLD | — | 0.8% | +0.4% | 4.0 | 108,000 | +0 | 3 | +136.9% |
| ☆BMEA funds › | BIOMEA FUSION INC | HOLD | — | 0.6% | -0.0% | 3.0 | 2,048,757 | +0 | 5 | — |
| ☆ACRS funds › | ACLARIS THERAPEUTICS INC | HOLD | Common Stock | 0.5% | +0.1% | 2.3 | 434,455 | +0 | 5 | — |
| ☆EPRX funds › | EUPRAXIA PHARMACEUTICALS INC | HOLD | — | 0.5% | -0.0% | 2.1 | 325,000 | +0 | 2 | -65.6% |
| ☆VTVT funds › | VTV THERAPEUTICS INC | NEW | — | 0.4% | +0.4% | 1.9 | 50,000 | +50,000 | 1 | -73.7% |
| ☆MRKR funds › | MARKER THERAPEUTICS INC | HOLD | — | 0.1% | +0.0% | 0.5 | 325,370 | +0 | 5 | — |
| ☆OKUR funds › | ONKURE THERAPEUTICS INC | HOLD | — | 0.1% | +0.0% | 0.4 | 88,607 | +0 | 5 | — |
Point-in-time history
| Period | AUM ($M) | Positions | Turnover | Top-10 wt | Herfindahl | Quality Q | Skill | Universe |
|---|---|---|---|---|---|---|---|---|
| 2026Q2 | 472 | 14 | 0.08 | 99% | 0.539 | 0.894 | — | in |
| 2026Q1 | 476 | 13 | 0.03 | 99% | 0.638 | 0.929 | — | in |
| 2025Q4 | 479 | 13 | 0.17 | 100% | 0.668 | 0.767 | — | in |
| 2025Q3 | 456 | 14 | 0.06 | 99% | 0.505 | 0.894 | — | in |
| 2025Q2 | 360 | 13 | 0.03 | 100% | 0.559 | 0.915 | — | entered |
| 2025Q1 | 288 | 13 | 0.00 | 99% | 0.551 | 0.000 | — | out |
Long US-equity 13F disclosures only · up to 45-day reporting lag · sells = reduce/avoid, not short.
JSON: /api/signals ·
/api/funds ·
/api/status